AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

BridgeBio Pharma, Inc. Director's Dealing 2025

Feb 28, 2025

30604_dirs_2025-02-27_21ac787c-6dac-4b1d-8f0f-d37e40c38878.zip

Director's Dealing

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-02-19

Reporting Person: Apuli Maricel (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	125005	Direct